Current studies demonstrated that exogenous VEGF can protect AML cells from chemotherapy-induced apoptosis (Jayson et al., 2016), and agents against VEGF/VEGFR pathway, including anti-VEGF antibody and small molecular tyrosine kinase inhibitors, have been introduced in leukemia therapy (Madlambayan et al., 2010). The gene discussed is VEGFA; the disease is acute myeloid leukemia.